surpass cvot tirzepatide Efficacy and safety of in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial Long-awaited SURPASS-CVOT: Cardiovascular Outcomes with

Patients should maintain adequate hydration and seek prompt medical advice if persistent vomiting, diarrhoea, or signs of dehydration occur

Tuesday 21 October (Central Daylight Time six hours behind UK time) Core Interactive Session Translating OSA Endophenotyping into Clinical Trials (91510:15am CDT) Rapid-Fire Oral: SynAIRgy Phase 3 Trial 1:451:50pm CDT Poster: LunAIRo 51-week Phase 3 Trial 1:452:30pm CDT Additional posters explore the impact of OSA on productivity and the economic burden of fatigue and daytime sleepiness

Why Does Tirzepatide Cause Fatigue

More than a billion people live with obesity worldwide, with rates rising fast in lower-income nations as they shift to westernised diets and more sedentary lifestyles

Five minutes if you can manage it

Weight loss, appetite changes, and blood sugar improvements are much more reliable indicators